intranas
administr
synthet
sirna
effect
modal
rnai
deliveri
prevent
therapi
respiratori
diseas
includ
pulmonari
infect
vehicl
use
nasal
sirna
deliveri
includ
establish
well
novel
reagent
mani
recent
optim
gener
promot
signific
uptak
sirna
lower
respiratori
tract
includ
lung
properli
design
optim
sirna
offer
signific
protect
respiratori
virus
influenza
viru
parainfluenza
viru
respiratori
syncyti
viru
rsv
nasal
administ
sirna
remain
within
lung
access
system
blood
flow
judg
absenc
major
organ
liver
heart
kidney
skelet
muscl
advers
immun
reaction
gener
encount
especi
immunogen
andor
offtarget
sirna
sequenc
toxic
vehicl
avoid
fact
sirna
rsv
enter
phase
ii
clinic
trial
human
promis
result
provid
standard
procedur
use
nose
specif
rout
sirna
deliveri
lung
laboratori
anim
clear
simpl
effici
system
enorm
potenti
therapeut
multiprotein
rnaiinduc
silenc
complex
risc
catalyt
compon
risc
specif
cleav
target
rna
strand
within
risc
thu
destroy
target
clearli
rnai
offer
high
specif
efficaci
turn
express
target
gene
first
success
antivir
applic
sirna
mammal
demonstr
rsv
cell
cultur
efficaci
later
translat
mous
model
rsv
infect
rsv
nonseg
singlestrand
rna
viru
paramyxovirida
famili
addit
rsv
number
seriou
lifethreaten
human
domest
anim
virus
eg
mump
measl
parainfluenza
borna
rabi
ebola
hendra
nipah
belong
famili
note
influenza
flu
viru
belong
orthomyxovirida
famili
also
rna
viru
contain
segment
genom
thu
intranas
rnai
approach
also
effect
respiratori
viral
diseas
includ
flu
sar
nasal
rout
repres
improv
sirna
deliveri
regimen
compar
system
approach
intraven
intraperiton
hydrodynam
tail
vein
inject
sinc
conveni
noninvas
therapeut
effect
may
also
prove
use
treat
debilit
noninfecti
respiratori
diseas
chronic
obstruct
pulmonari
diseas
copd
cystic
fibrosi
asthma
perhap
form
lung
cancer
combin
exist
anticanc
drug
sirna
protect
ethyl
orthoest
chemistri
see
note
depctreat
water
rnasefre
aerosol
resist
pipett
tip
rnasefre
microfug
tube
dri
pellet
store
use
resuspend
sirna
buffer
anoth
appropri
buffer
solut
prepar
sirnavehicl
complex
immedi
nasal
administr
determin
optim
sirna
amount
titer
nmol
per
mous
steril
rnasefre
plastic
tube
add
ml
optimem
reducedserum
medium
add
ml
transittko
transfect
reagent
tube
contain
optimem
medium
mix
thoroughli
vortex
incub
room
temperatur
min
add
desir
amount
sirna
ml
sirna
buffer
dilut
transittko
reagent
care
mix
gentl
pipet
incub
room
temperatur
min
prior
nasal
administr
sirna
mice
see
note
must
anesthet
minim
pain
discomfort
nembut
administ
intraperiton
ip
inject
recommend
drug
dosag
mgkg
test
desir
rnai
effect
appropri
interv
antivir
studi
instil
viru
nostril
well
human
rsv
infect
mice
well
use
viru
particl
per
anim
measur
standard
lung
titer
assay
clinic
symptom
bodi
weight
respir
rate
assum
reader
expertis
design
sirna
given
target
gener
follow
design
suit
offer
dharmacon
thermo
scientif
whitehead
institut
mit
cambridg
web
page
also
tri
avoid
rel
strong
immunogen
sequenc
essenti
rna
viral
gene
essenti
robust
viru
growth
henc
sirna
design
viral
mrna
inhibit
viru
replic
nonetheless
gener
target
compon
viral
rna
synthesi
machineri
paramyxovirida
l
larg
protein
rnadepend
rna
polymeras
p
phosphoprotein
transcript
factor
l
n
nucleocapsid
protein
essenti
templat
function
viral
genom
rna
reason
anim
ethic
costsav
alway
test
new
sirna
sequenc
cell
cultur
antivir
potenc
measur
progeni
viral
titer
use
rang
concentr
nm
potent
sirna
exhibit
inhibit
low
nm
concentr
eg
concentr
nm
criteria
use
design
recommend
note
experienc
success
rate
sirna
year
step
subhead
need
fulli
deprotect
anneal
readytous
sirna
purchas
commerci
expens
save
cost
usual
purchas
protect
rna
deprotect
modif
increas
stabil
rna
shipment
storag
describ
simpl
method
nasal
deliveri
sirna
mous
model
success
scale
use
laboratori
anim
diminish
possibl
toxic
effect
deliveri
reagent
sirna
introduc
nake
ie
without
transfect
reagent
exhibit
activ
reagentcomplex
sirna
best
use
polyethyleneimin
pei
although
pei
often
use
form
complex
nucleic
acid
mice
toler
pei
nose
although
deliveri
avenu
intraven
well
toler
attempt
essenti
mice
die
within
minut
inhal
peisirna
complex
new
gener
transfect
reagent
constantli
report
may
provid
better
deliveri
administr
excess
liquid
drown
mous
caus
death
tri
keep
total
volum
ml
routin
applic
although
ml
may
toler
intranas
procedur
also
work
aerosol
applic
use
small
homemad
enclosur
anesthet
mous
place
sirna
complex
made
subhead
spray
handheld
nebul
common
type
use
inhal
asthmat
method
howev
larger
amount
sirna
need
mist
get
wast
small
fraction
inhal
anim
optim
cost
vs
benefit
recommend
variou
amount
mist
durat
exposur
test
optim
given
enclosur
volum
method
routin
use
commerci
motor
nebul
easili
optim
recommend
check
local
pediatr
depart
exact
model
vendor
usag
modifi
system
remov
plastic
face
cup
mask
deliveri
end
insert
tube
directli
mous
enclosur
reagent
cost
reduc
design
smaller
face
cup
snugli
fit
mous
nose
area
